Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 6/20 | 0.86 |
| ▸ | OXTR | P30559 | 15/20 | 0.85 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.85 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demoxytocin SCHEMBL38443 | 0.97 | AVPR1A (0.88) | AVPR1AOXTRAVPR2AVPR1B | |
| Demoxytocin SCHEMBL29376547 | 0.97 | AVPR1A (0.88) | AVPR1AOXTRAVPR2AVPR1B | |
| Demoxytocin SCHEMBL38442 | 0.97 | AVPR1A (0.88) | AVPR1AOXTRAVPR2AVPR1B | |
| Oxytocin SCHEMBL28086558 | 0.94 | OXTR (0.93) | AVPR1AOXTRAVPR2AVPR1B | |
| SCHEMBL15511596 | 0.93 | AVPR1A (1.00) | AVPR1AOXTRAVPR2AVPR1B | |
| SCHEMBL15511632 | 0.92 | AVPR1A (0.80) | AVPR1AOXTRAVPR2AVPR1B | |
| SCHEMBL15511808 | 0.92 | AVPR1A (0.87) | AVPR1AOXTRAVPR2AVPR1B | |
| Oxytocin SCHEMBL1173243 | 0.92 | OXTR (1.00) | AVPR1AOXTRAVPR2AVPR1B | |
| Oxytocin SCHEMBL20707334 | 0.92 | OXTR (1.00) | AVPR1AOXTRAVPR2AVPR1B | |
| Oxytocin SCHEMBL21527573 | 0.92 | OXTR (1.00) | AVPR1AOXTRAVPR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213648-A1 | OXYTOCIN COMPOSITIONS AND METHODS | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2025-07-03 | — | — | US | disclosed |
| EP-4543415-A1 | OXYTOCIN FORMULATION | Hikma Pharmaceuticals USA Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20240139278-A1 | OXYTOCIN FORMULATION | XELLIA PHARMACEUTICALS APS (DK) | 2024-05-02 | — | — | US | disclosed |
| WO-2023247760-A1 | OXYTOCIN FORMULATION | XELLIA PHARMACEUTICALS APS (DK) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139278-A1 | OXYTOCIN FORMULATION | OXTR, AVPR2, AVPR1B | AVPR1A 4/4885OXTR 1/4885AVPR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.